Navigation Links
Codexis Names Vice President, Intellectual Property
Date:9/23/2008

REDWOOD CITY, Calif., Sept. 23 /PRNewswire/ -- Codexis, Inc., today announced the appointment of Lynn Marcus-Wyner, Ph.D., as Vice President, Intellectual Property. She will be responsible for managing the company's intellectual property strategy, activities, and patent portfolio and will report to Douglas Sheehy, Vice President, General Counsel and Secretary.

Dr. Marcus-Wyner joins Codexis from Danisco A/S, where as Senior Director, Intellectual Assets US, she managed the United States patent department of the Genencor division. Previously, she was in private intellectual property law practice representing clients, including Genencor International, Inc., and Novartis Corporation, and held a legal patent management position at Sandoz Agro Inc. Dr. Marcus-Wyner was also a Patent Attorney at Zeneca Inc. (formerly ICI Americas Inc). Dr. Marcus-Wyner has a J.D. from the University of the Pacific, McGeorge School of Law and a Ph.D. in plant physiology from the University of California, Davis. Prior to law school, Dr. Marcus-Wyner was an Assistant Professor in the Plant and Soil Science Department at the University of Massachusetts, Amherst.

"Building and protecting our intellectual property portfolio is a key success factor for Codexis," Mr. Sheehy said. "Dr. Marcus-Wyner has broad experience counseling life science and bioindustrial companies on intellectual property law matters, and brings a proven track record in managing this important function in our industry," Mr. Sheehy said. "We are very pleased to add her to the Codexis legal team."

Codexis is a leading developer of proprietary biocatalysts that the company believes have the potential to revolutionize chemistry-based manufacturing processes across a variety of industries. The company has used its technology platform to enable biocatalyst-based commercial-scale drug manufacturing processes and delivered biocatalysts and drug products to some of the world's leading pharmaceutical companies. Codexis has a funded research collaboration in the biofuels market, and the company is pursuing funded collaborations in several other bioindustrial markets, including carbon management, water treatment and chemicals.
CONTACT: Lyn Christenson, lyn.christenson@codexis.com,

650-421-8144, or Justin Jackson, jjackson@burnsmc.com,

Burns McClellan, 212-213-0006


'/>"/>
SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis, Arch Announce Expanded Collaboration
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Names David Anton VP Bioindustrials R&D
4. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
5. Rothwell, Wolf Elected to Codexis Board
6. Codexis Opens Singapore Laboratory
7. Bruce Pasternack Elected to Codexis Board
8. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
9. Codexis Appoints Singapore Laboratories Managing Director
10. Genstruct Names Louis Latino VP of Sales
11. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  BioGenex, a ... announce development of a novel system for quantitative ... with the University of Rochester (NY, USA) and ... The new system is able to accurately quantify ... HER2 (Human epidermal growth factor receptor-2) in clinical ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be hosting a ... held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). BioMixers ... an opportunity to interact with peers, make new connections and talk bio biz. , ...
(Date:2/16/2017)... -- Research and Markets has announced the ... report to their offering. ... The study scope ... plasmids, chassis organisms, synthetic cells, production systems), enabling technologies ... and specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... Series 1a financing and entered into a $5 ...  Dermata intends to use the capital for general ... major advancements in the treatment of serious diseases ...
Breaking Biology Technology:
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
(Date:1/12/2017)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer ... it has signed agreements with seven strategic partners across ... Middle East for commercialization of the Trovera™ ... of international distribution agreements for Trovagene,s CLIA based liquid ... The initial partners will introduce Trovagene,s liquid biopsy tests ...
Breaking Biology News(10 mins):